Identification of Potential Prognostic Biomarkers for Tongue Squamous Cell Carcinoma

Mi Zhang⁠¹,², Sihui Zhang⁠¹,², Ling Wu⁠¹,², Dexiong Li⁠¹,², Jiang Chen⁠¹,²*

¹ School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China
² Fujian Key Laboratory of Oral Diseases & Fujian Provincial Engineering Research Center of Oral Biomaterial & Stomatological Key lab of Fujian College and University, School and Hospital of Stomatological, Fujian Medical University, Fuzhou, China

*Correspondence:
Jiang Chen,
jiangchen@fjmu.edu.cn

Keywords: tongue squamous cell carcinomas, long noncoding RNA, messenger RNA, biomarkers, prognosis, overall survival.

Abstract

Background: Tongue squamous cell carcinoma (TSCC) is one of the most common types of oral cancer and has a poor prognosis owing to a limited understanding of the pathogenesis mechanisms. The purpose of this study was to explore and identify potential biomarkers in TSCC by integrated bioinformatics analysis.

Methods: The RNA sequencing data and clinical characteristics of TSCC patients were downloaded from The Cancer Genome Atlas (TCGA), and then differentially expressed RNAs (DERNAs), including differentially expressed long noncoding RNAs (DElncRNAs) and differentially expressed messenger RNAs (DEmRNAs), were identified in TSCC by bioinformatics analysis. Subsequently, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Hallmark pathway analyses were used to analyze the DERNAs. Using univariate and multivariate Cox regression analyses, four-lncRNA and two-mRNA signatures were developed and used for predicting survival in TSCC patients. We established a risk model to predict the overall survival (OS) of TSCC patients based on the DERNAs with Kaplan–Meier analysis and the log-rank p test. Furthermore, weighted gene coexpression network analysis (WGCNA) was performed in Cytoscape, and a protein-protein interaction (PPI)
network was established in the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database.

**Results:** A total of 2,006 DEmRNAs and 1,001 DElncRNAs were found to be dysregulated in TSCC. A total of 417 DERNAs were used to construct the coexpression network, and the PPI network included 103 DEmRNAs. Univariate regression analysis of the DERNAs revealed 51 DElncRNAs and 90 DEmRNAs that were associated with OS in TSCC patients. Multivariate Cox regression analysis demonstrated that four of those lncRNAs (MGC32805, RP1-35C21.2, RP11-108K3.1, RP11-109M17.2) and two mRNAs (CA9, GTSF1L) had significant prognostic value, and their cumulative risk score indicated that these four-lncRNA and two-mRNA signatures independently predicted OS in TSCC patients.

**Conclusions:** The current findings provide novel insights into the molecular mechanisms of TSCC and identify four lncRNAs and two mRNAs that are potential biomarkers that may be independent prognostic signatures for TSCC diagnosis and treatment.
1. Introduction

Tongue squamous cell carcinoma (TSCC) is one of the most common and lethal types of oral cancer\textsuperscript{[1]}, and is characterized by poor prognosis, frequent lymphatic metastasis, and a high rate of regional recurrence. Currently, the most preferred treatment for TSCC is surgery combined with postoperative radiotherapy and chemotherapy. However, the 5-year overall survival (OS) rate of TSCC has not improved significantly over the past decades. It is pivotal to diagnose TSCC in the early stage. Therefore, elucidating the molecular mechanisms and exploring effective molecular therapeutic targets play essential roles in improving the survival rate of patients with TSCC.

Less than 2% of the human genome contains protein-coding genes, while the majority of transcripts are non-protein-coding RNAs\textsuperscript{[2]}. Among them, long noncoding RNAs (lncRNAs) are RNA transcripts longer than 200 nucleotides and have no obvious protein-coding capacity. LncRNAs affect various aspects of biological processes in TSCC, including cell proliferation, tumorigenesis, survival, apoptosis, and migration\textsuperscript{[3]}\textsuperscript{[4]}\textsuperscript{[5]}\textsuperscript{[6]}. However, the underlying mechanisms have not been fully clarified. Moreover, the expression patterns of cancer-specific lncRNAs seems to be more tissue- and stage-specific than those of protein-coding genes, indicating the potential development of lncRNAs as promising alternative biomarkers and therapeutic targets\textsuperscript{[7]}. To date, multiple lncRNAs have been identified in TSCC. For example, upregulation of the lncRNA FALEC suppresses malignant behaviors in TSCC\textsuperscript{[6]}. Overexpression of the lncRNA HOTTIP in TSCC patients indicates a poor clinical prognosis\textsuperscript{[5]}. Moreover, the lncRNAs KCNQ1OT1 and SNHG17 act as competing endogenous RNAs (ceRNAs) to control cell proliferation and cancer progression in TSCC\textsuperscript{[3, 8]}. In addition, recent studies revealed that lncRNA combined with mRNA biomarkers could improve diagnosis\textsuperscript{[9]}\textsuperscript{[10]}. However, there are limited valuable lncRNA and mRNA biomarkers used for the diagnosis of TSCC.

In this study, we aimed to analyze the differentially expressed profile of noncoding RNAs in TSCC and establish a Cox regression model to predict the OS of patients with TSCC. Moreover, we constructed a lncRNA-mRNA coexpression network and a protein-protein interaction (PPI) network. Our findings provide novel insights and may
be conducive to understanding the molecular mechanisms. Further, verification of the IncRNAs and mRNAs could provide new therapeutic targets for TSCC.
2. Materials and methods

2.1 Patient information collection and data preparation

Data associated with TSCC, including the RNA sequencing (RNA-Seq) data of transcriptome profiling and clinical data, were retrieved from The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/) and were downloaded through the Genomic Data Commons (GDC) data transfer tool. In the predictive survival-related model, we excluded 27 samples because they lacked complete clinical data. Finally, 146 TSCC samples (119 samples for the predictive survival-related model) and 15 normal control samples were collected in our study.

2.2 Data processing and differentially expressed gene analysis

The EdgeR package in R (version 3.6.3) was used to identify the differentially expressed mRNAs (DEmRNAs) with the thresholds of \(|\log_2 \text{fold change [FC]}|>2.0\) and false discovery rate (FDR) (adjusted \(p\)-value) \(<0.05\) \[^{[11]}\). Then, we used the annotation file in GTF format (Homo_sapiens.GRCh38.100.chr.gtf) to identify and annotate differentially expressed lncRNAs (DElncRNAs) with the thresholds of \(|\log_2 \text{FC}|>2.0\) and FDR\(<0.05\). A heatmap and volcano plot were constructed by the gplots package in R software. A scatter diagram and paired plot were generated by the Wilcoxon test in R software.

2.3 Cell lines

Two human TSCC cell lines, CAL-27 and SCC-9 were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA), and the human normal oral keratinocyte (hNOK) cell line was obtained from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). CAL-27 cells and hNOK cells were grown in DMEM (Gibco) supplemented with 10% FBS (Invitrogen, Carlsbad, CA, USA). SCC-9 cells were cultured in DMEM/F-12 (Gibco) supplemented with 10% FBS and 0.4 \(\mu\)g/ml hydrocortisone. All cells were maintained at 37°C in an incubator supplied with 5% CO2.

2.4 RNA extraction and quantitative real-time PCR analysis

Total RNA was extracted from cells using TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer’s instructions. Total RNA was reverse transcribed into
cDNA using a PrimeScript RT reagent kit (TaKaRa). RT-qPCR analyses were performed using SYBR Green Master Mix (TaKaRa). This process was performed using an Applied Biosystems 7500 Real-Time PCR System. The results were normalized to the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The relative expression level was calculated by the 2-ΔΔ Ct method. The primers were provided by the SunYa Company.

2.5 Functional enrichment analysis

Gene Ontology (GO) analysis included biological processes, cellular components and molecular functions. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was used to annotate the potential functions. GO and KEGG functional analyses were conducted for the DEmRNAs. A significance level of \( p < 0.05 \) was set as the cutoff criteria, and the plots were constructed by the ggplot2 and clusterProfiler packages in R software [12].

2.6 Gene set enrichment analysis (GSEA)

The presumptive biological roles of the DElncRNAs correspond to those of their associated mRNAs. The expression profile data were ranked according to the signature score, and the data were divided into a high-risk group and a low-risk group by the mean score. Then, GSEA (version 4.0.3) software was used for analysis.

2.7 Cox risk regression model construction and validation

The OS and hazard ratios (HRs) were calculated by the Kaplan–Meier algorithm and univariate Cox regression analysis, respectively. The log-rank method was used to test the differences between the survival curves. The univariate Cox proportional hazards regression method was applied to analyze the relationships between the DElncRNAs and OS when the significance level was set at 0.05 to determine those with prognostic value in TSCC. We used the following formula to establish a prognostic risk score model: Risk score = \( \exp_{\text{lncRNA}_1} \beta_{\text{lncRNA}_1} + \exp_{\text{lncRNA}_2} \beta_{\text{lncRNA}_2} + \cdots \exp_{\text{lncRNA}_n} \beta_{\text{lncRNA}_n} \); Risk score = \( \exp_{\text{Gene}_1} \beta_{\text{Gene}_1} + \exp_{\text{Gene}_2} \beta_{\text{Gene}_2} + \cdots \exp_{\text{Gene}_n} \beta_{\text{Gene}_n} \) (where \( \exp \) is the expression level of the prognostic DElncRNA or DEmRNA and \( \beta \) is the corresponding multivariate Cox regression model regression coefficient). The gene signature score as a prognostic predictor for TSCC patients was evaluated in the model.
We determined the significant variables through univariate Cox regression analysis. Candidate variables with a \( p \)-value of < 0.015 for DElncRNAs and a \( p \)-value of < 0.01 for DEmRNAs in univariate analysis were included in the multivariable model. Setting the median risk score as the threshold, the TSCC patients were stratified into high- and low-risk groups. The survival ROC package in R was used to construct time-dependent receiver operating characteristic (ROC) curves within 5 years as the defining point and to calculate the risk prediction rate of specific lncRNAs and mRNAs between the two groups. Finally, univariate and multivariate analyses were implemented to evaluate the effects of other clinical variables of TSCC patients on the OS risk score. R software was used for all statistical analyses.

2.8 **Weighted gene coexpression network analysis (WGCNA)**

The WGCNA package in R was used to construct a coexpression network utilizing the expression values of the mRNAs and lncRNAs screened above. In brief, we constructed the weighted adjacency matrix using a power function based on a soft-thresholding parameter \( \beta \). In this study, we chose a \( \beta \) value of 12. The DElncRNA and DEmRNA coexpression network was visualized in Cytoscape (Version 3.7.2) software. Subsequently, module analysis \(^{[13]}\) of the coexpression network was performed using the Molecular Complex Detection (MCODE) tool of Cytoscape software.

2.9 **PPI analysis**

The DEmRNAs with FDR < 0.001 and confidence score > 0.9 were included in the PPI network through the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (https://string-db.org/), and the PPI network was visualized in Cytoscape. The subnetworks were analyzed by the MCODE tool, and GO and KEGG analyses of the modules was carried out using R software.

2.10 **Statistical analysis**

All statistical analyses were performed using R software. For the survival analysis, the differences between two groups were assessed by the log-rank p test, and for the paired plot analysis, the differences between two groups were assessed by the Wilcoxon test. \( P \)-values < 0.05 were considered statistically significant.

3. **Results**
3.1 Identification of DElncRNAs and DEmRNAs

The RNA expression profiles and corresponding clinical data of 146 TSCC patients and 15 normal controls were downloaded from the TCGA database. \(|\text{Log2FC}| > 2\) and FDR < 0.05 were used as the thresholds. A total of 1,001 DElncRNAs (680 upregulated and 321 downregulated, Figure 1A) and 2,006 DEmRNAs (856 upregulated and 1,150 downregulated, Figure 1B) were identified.

3.2 Functional analysis of the DEmRNAs

GO and KEGG enrichment analyses were used to explore the potential functions of the DEmRNAs. The results indicated that these genes were mainly enriched in extracellular structure organization, cell differentiation and transporter activity (Figure 2C). In addition, KEGG pathway analyses demonstrated that the most significant pathways were the starch and sucrose metabolism, glycine, serine and threonine metabolism and glycolysis/gluconeogenesis pathways (Figure 2D).

3.3 Establishment of the differentially expressed RNA (DERNA) prognostic model

First, univariate Cox regression analysis and Kaplan–Meier analysis (log-rank p test) were used to identify lncRNAs associated with the OS of TSCC patients. With the significance level cutoff threshold set at \(p < 0.05\) (Table 1), a total of 51 lncRNAs were associated with the OS of TSCC patients. After Kaplan–Meier analysis was performed, as shown in Figure 3, several lncRNAs including AC007879.5, FOXD2-AS1, LINC01615, MGC32805, PLS3-AS1, RP1-35C21.2, RP11-108K3.1, RP11-109M17.2, RP11-275N1.1, RP11-497D6.3 and RP11-502M1.2 were detected to have significant prognostic value.

Then, 17 candidate DElncRNAs with \(p\)-value < 0.015 were all fitted into the multivariate Cox regression model. The results indicated that SLC8A1-AS1, FOXD2-AS1, MGC32805, RP11-108K3.1, PLS3-AS1, RP3-449H6.1, RP11-109M17.2, RP11-11N5.3, RP1-35C21.2 and RP11-865I6.2 had significant prognostic value in TSCC (Table 2), and all candidate lncRNAs involved in the multivariate Cox regression model were used to develop a lncRNA prognostic model.

We also adopted the same approach to verify the mRNAs associated with the OS of TSCC patients (Table 3), and a total of 90 mRNAs were associated with the OS of
TSCC patients. As shown in Figure 4, many mRNAs, including ADH1B, ASCL4, C6, CA9, FAM65C, GNG8, GTSF1L, ODF4, OVOS2, PCK1, and SHOX2, were found to have significant prognostic value. Fifteen candidate DEmRNAs with \( p \)-value < 0.01 were all fitted into the multivariate Cox regression model, and the results showed that CA9, OVOS2, LRRTM3, C7, GTSF1L, PCK1, F2RL2 and ODF4 had significant prognostic value in TSCC (Table 4).

Risk score analysis of the lncRNAs was performed for each patient, and based on the risk scores, the patients were divided into the low-risk and high-risk groups. The survival rate of the low-risk patients was significantly higher than that of the high-risk patients (Figure 5E). The heatmap in Figure 5F shows the relationships between the expression of 12 candidate lncRNAs and the risk status of each patient. The 5-year survival correlation of the 12-lncRNA signature was assessed by ROC analysis, and the area under the curve (AUC) was computed to assess the discriminatory capacity of the lncRNA signature (Figure 5G). The AUC of the 12-lncRNA signature was 0.876, indicating its utility as a prognostic model for predicting the survival status of TSCC patients. Significantly, we found that FOXD2-AS1, MGC32805, PLS3-AS1, RP1-35C21.2, RP11-108K3.1, and RP11-109M17.2 were simultaneously identified to be associated with OS in Kaplan–Meier and multivariate Cox regression analyses. Moreover, risk score analysis of the eight candidate mRNAs was performed for each patient (Figure 5H) and a heatmap was constructed (Figure 5I). Subsequently, the ROC curve was plotted, and the AUC was 0.84 (Figure 5J). Likewise, CA9, GTSF1L, ODF4, OVOS2, and PCK1 were simultaneously verified to be associated with OS in Kaplan–Meier and multivariate Cox regression analyses.

The expression of FOXD2-AS1, MGC32805, PLS3-AS1, RP1-35C21.2, RP11-108K3.1 and RP11-109M17.2 was then analyzed in TSCC and normal tissues, as well as in the low- and high-risk paired groups (Figure 6). FOXD2-AS1, PLS3-AS1, RP1-35C21.2, RP11-108K3.1, and RP11-109M17.2 were expressed at high levels, and MGC32805 was expressed at low levels in TSCC patients. Similarly, the expression of CA9, GTSF1L, ODF4, OVOS2, and PCK1 was analyzed in the tumor and normal tissues, as well as in the paired groups (Figure 7). CA9, GTSF1L, and OVOS2 were
expressed at high levels, and ODF4 and PCK1 were expressed at low levels in TSCC patients.

3.4 Prognostic value of the four-lncRNA and two-mRNA signatures in TSCC

Univariate regression analysis was then used to predict the potential risk factors for the long-term all-cause death of patients, including age, sex, grade, stage, T stage, and the expression of each lncRNA or mRNA. Multivariate regression models were conducted to assess the prognostic power of each lncRNA and mRNA signature separately. Potential risk factors with $p < 0.05$ were included in the multivariate Cox regression analysis to screen independent risk factors for predicting long-term death. Univariate analysis indicated that grade, stage, T stage, and N stage were significantly correlated with the OS of TSCC patients ($p < 0.05$) (Supplementary Table 1). As with the DElncRNAs, the DEmRNA results were obtained using the same approach (Supplementary Table 2). Of particular note, multivariate analysis found that the expression of MGC32805, RP1-35C21.2, RP11-108K3.1, RP11-109M17.2, CA9 and GTSF1L were significantly correlated with the OS of TSCC patients ($p < 0.05$) (Figure 8).

3.5 GSEA of the four-lncRNA and two-mRNA signatures

The GSEA results showed that for patients with high signature scores, MGC32805 was mainly enriched in the GO terms of RNA binding and nuclease activity; RP1-35C21.2 was mainly enriched in the GO molecular function terms of regulator and regulation of lymphocyte apoptotic process; RP11-108K3.1 was mainly enriched in the GO terms of identical protein binding and positive regulation of cellular component biogenesis; RP11-109M17.2 was mainly enriched in the GO terms of RNA splicing and mRNA splice site selection; and CA9 was mainly enriched in the GO terms of pyruvate metabolic process, nucleotide phosphorylation, ADP metabolic process, steroid hydroxylase activity, and aromatase activity. Moreover, the mainly enriched KEGG terms included cell cycle, mTOR signaling pathway, glycolysis/gluconeogenesis, spliceosome, and RNA degradation. In addition, for patients with high signature scores, CA9 was mainly enriched in the Hallmark terms of glycolysis, mTORC1 signaling, hypoxia, MYC targets V2, and PI3K/AKT/MTOR signaling. For GTSF1L, those with
high signature scores showed enrichment in the GO terms of immune receptor activity, negative regulation of lymphocyte activation, regulation of B cell activation, regulation of leukocyte proliferation, and regulation of T cell activation; mainly showed enrichment in KEGG terms including B cell receptor signaling pathway, cytokine-cytokine receptor interaction, JAK/STAT signaling pathway, natural killer cell-mediated cytotoxicity, and T cell receptor signaling pathway; and mainly showed enrichment in the Hallmark terms of complement, IL2/STAT5 signaling, IL6/JAK/STAT3 signaling, inflammatory response, and MYC target V1 ($p < 0.05$; Figure 9; Supplementary Table 3).

### 3.6 Weighted gene coexpression network construction

Moreover, a coexpression network was constructed successfully. The expression levels of 3,007 genes, including 2,006 mRNAs and 1,001 lncRNAs, were used for coexpression network construction by the WGCNA package. In the current study, to ensure a scale-free network, we selected $\beta = 12$ as the soft-thresholding power (Supplementary Figure 1). Then, the coexpression network was constructed by 417 DERNAs and visualized in Cytoscape. Subsequently, three subnetworks of the coexpression network were constructed by using the MCODE tool of Cytoscape (Figure 10).

### 3.7 PPI network analysis

The PPI network contained a total of 619 proteins and 2,639 edges. With the thresholds of confidence score $> 0.9$, 103 genes were selected to construct three subnetworks with degree $\geq 20$ by using the MCODE tool of Cytoscape (Figure 11). According to GO term analysis, the three modules were related to extracellular matrix component, G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger, actin binding, and posttranslational protein modification, showing that the genes in these modules play a pivotal role in cancer. Regarding the KEGG enrichment analysis, module 1 regulated metabolic pathways such as protein digestion and absorption, human papillomavirus infection, and the PI3K-Akt signaling pathway. Module 2 was significantly associated with hypertrophic cardiomyopathy (HCM). Moreover, module 3 was significantly related to the chemokine signaling pathway,
calcium signaling pathway, and cAMP signaling pathway, which are associated with the genesis and progression of tumors (Supplementary Tables 4, 5, and 6).

3.8 Validation of the biomarkers

In summary, all the above results show that four lncRNAs, including MGC32805, RP1-35C21.2, RP11-108K3.1, and RP11-109M17.2, and two mRNAs, including CA9 and GTSF1L, were simultaneously identified to be associated with the OS of TSCC patients. Thus, they could act as potential prognostic biomarkers in TSCC. The differential expression information of the biomarkers is shown in Supplementary Table 7. qRT-PCR was performed to verify the expression levels of the candidate biomarkers in TSCC cell lines. The expression of MGC32805, RP1-35C21.2, RP11-108K3.1, RP11-109M17.2, CA9, and GTSF1L were consistent with the sequencing results (Figure 12). All primers information are listed in Supplementary Table 8.
4. Discussion

TSCC is a common lethal malignant cancer, and the lack of specific diagnostic and prognostic biomarkers contribute to the currently low 5-year survival rate of TSCC patients. Therefore, it is crucial to explore the comprehensive regulatory mechanisms of TSCC initiation and progression and to identify potential biomarkers for the early diagnosis and prognosis of TSCC that are predictive of outcomes.

Emerging evidence indicates that most lncRNAs play essential roles in TSCC progression, with diverse underlying mechanisms. In this study, a total of 2,006 DEmRNAs and 1,001 DElncRNAs were identified. GO analysis demonstrated that the functions of the DERNAs were mainly associated with extracellular structure organization, cell differentiation and transporter activity, which play vital roles in tumorigenesis. In addition, KEGG pathway analyses revealed that the most significant pathways were the starch and sucrose metabolism, glycine, serine and threonine metabolism and glycolysis/gluconeogenesis pathways. All of these pathways are significantly associated with cancers. For example, the genetic activation of serine biosynthesis has been indicated to directly drive cancer proliferation; intriguingly, genetic and functional evidence supports the importance of the activity of serine and glycine biosynthesis as drivers of oncogenesis \[^{14}\]. Furthermore, differentially expressed proteins showed significant enrichment for the glycolysis/gluconeogenesis pathways in breast cancer patients \[^{15}\].

With the goal of identifying lncRNAs and mRNAs significantly associated with OS, we established a Cox regression model to predict the OS of patients with TSCC. Univariate regression analysis of the DElncRNAs identified 17 candidate lncRNAs associated with OS. Multivariate analysis showed that 12 of them were related to OS, and 10 of those lncRNAs were significantly associated with OS (\(p<0.05\)). A cumulative risk score of the 12 lncRNAs was calculated, which indicated that they may independently predict OS in TSCC patients. Then, six of these lncRNAs were identified to have significant prognostic value after Kaplan–Meier analysis was carried out. The same approach was also applied for the DEmRNAs. Univariate and multivariate regression analyses were then used to predict the potential risk factors for long-term
all-cause death in TSCC patients. Four of those lncRNAs (MGC32805, RP1-35C21.2, RP11-108K3.1, and RP11-109M17.2) and two mRNAs (CA9 and GTSF1L) were simultaneously identified to be associated with OS in TSCC patients. Moreover, we also established a lncRNA-mRNA coexpression network and a PPI network using the information obtained from the TCGA database. Our findings could help improve the understanding of lncRNA-mRNA coexpression regulatory mechanisms and provide new insights for therapeutic targets in TSCC.

In the current study, among these four lncRNA biomarkers, a genome-wide association study (GWAS) showed that MGC32805 may be involved in paclitaxel in vitro drug response phenotypes, which are moderately associated with the time to epithelial ovarian cancer recurrence [16]. Another GWAS revealed that the SNP rs146949893 in RP1-35C21.2 may be related to height [17]. In addition, previous studies have shown that RP11-108K3.1 could serve as a potential independent biomarker for the prognostic prediction of colorectal cancer [18]. RP11-108K3.1 is one of the DElncRNAs in lung adenocarcinoma [19]. However, no study so far has reported any association of RP11-109M17.2 with cancer, which means that it may serve as a novel therapeutic target in TSCC. All of these studies confirm that the DElncRNAs screened in our research play critical roles in tumor pathogenesis. However, the underlying mechanisms remain unknown. In our study, the GO analysis of the four lncRNAs showed that they were mainly enriched in RNA binding and nuclease activity, regulator and regulation of lymphocyte apoptotic process, identical protein binding and positive regulation of cellular component biogenesis, and RNA splicing and mRNA splice site selection. All of these processes are significantly associated with cancers.

For the two-mRNA signature, research has shown that high CA9 expression is related to poor prognosis and tumor grade in TSCC [20]; in addition, the GAA haplotype of 3 CA9 SNPs (rs2071676, rs3829078, and rs1048638) is correlated with a higher risk of oral cancer [21]. Natural selection shapes cancer genomes, and the study revealed that negative selection is a hallmark of cell essentiality and immune response in cancer. Although there was no significant difference, GTSF1L may be related to negative selection [22]. In addition, GTSF1L could also serve as a biomarker of common
reproductive impairments in males\textsuperscript{[23]}. In our findings, the KEGG analysis of CA9 and GTSF1L showed that they were mainly enriched in glycolysis/gluconeogenesis, the B cell receptor signaling pathway, the JAK/STAT signaling pathway, natural killer cell-mediated cytotoxicity, and the T cell receptor signaling pathway. Furthermore, the Hallmark analysis of CA9 and GTSF1L showed that they were mainly enriched in mTORC1 signaling, MYC targets V2, PI3K/AKT/MTOR signaling, IL2/STAT5 signaling, and IL6/JAK/STAT3 signaling. These pathways all play essential roles in tumor immunity.

In our study, the expression of MGC32805, RP1-35C21.2, RP11-108K3.1, RP11-109M17.2, CA9, and GTSF1L was then analyzed in TSCC and normal tissues, and their expression in the paired groups was also found to be significantly associated with poor clinical outcomes in TSCC patients. This is the first study to indicate the aberrant expression of MGC32805, RP1-35C21.2, RP11-108K3.1, and RP11-109M17.2 in TSCC and indicates a potential prognostic role of this 4-lncRNA signature in TSCC. In addition, our findings also support that CA9 and GTSF1L could be potential biomarkers in TSCC. The bioinformatics-based investigation of lncRNAs will contribute to future experimental research.

5. Conclusion

Taking all the above results together, we identified the four-lncRNA and two-mRNA signatures as potential prognostic biomarkers for TSCC patients by analyzing genome-wide lncRNA and mRNA expression data from the TCGA database. Furthermore, we established a lncRNA-mRNA coexpression network that is beneficial to understanding the relationships between lncRNAs and mRNAs and provides effective strategies for further functional studies of lncRNAs. Moreover, construction of the PPI network provides novel insights for TSCC treatment, and the risk score model contributes to improving OS in TSCC.

Limitations of the study

Although the findings of our study have crucial clinical implications, the limitations should also be noted. First, a longer follow-up duration is needed to confirm our results, and second, the findings based on the TCGA database need to be verified using cell
molecular experimental methods. In addition, subsequent functional studies are needed to elucidate the molecular mechanisms underlying the functions of the lncRNAs in TSCC, and the biological functions of MGC32805, RP1-35C21.2, RP11-108K3.1, RP11-109M17.2, CA9, and GTSF1L in TSCC also need to be further investigated.
Abbreviations
TSCC: tongue squamous cells carcinomas; lncRNA: long non-coding RNA; DEL: differentially expressed lncRNA; DEG: differentially expressed mRNA; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; WGCNA: weighted gene co-expression network analysis; PPI: protein-protein interaction.

Synonyms
RP1-35C21.2 (AL136114.1); RP11-108K3.1 (MIR4713HG); RP11-109M17.2 (AL162413.1).

Conflicts of interest
The authors declare no conflicts of interest.

Author Contributions
Research design and implementation: MZ, LW;
Data analysis and interpretation: MZ, SHZ;
Statistical analysis: LW, DXL;
Writing of the manuscript: MZ, SHZ;
Revision of the manuscript: JC.
All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (Nos. 81771126).

Acknowledgements
We would like to express our sincere thanks to all those who have helped us in the course of our writing this paper. We sincerely thank Fujian Key Laboratory of Oral Diseases of Fujian College and University (School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China) for technical guidance regarding the experiments described in this article.

Availability of data and materials
The datasets generated and analysed during the current study are available in The Cancer Genome Atlas (TCGA) repository (https://portal.gdc.cancer.gov/).

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.
Reference

[1] Mannelli G, Arcuri F, Agostini T, et al. Classification of tongue cancer resection and treatment algorithm. Journal of Surgical Oncology, 2018, 117(5):1092-1099.

[2] Sarah, Djebali, Carrie, et al. Landscape of transcription in human cells. Nature, 2012, 489:101-108.

[3] Zhang S, Ma H, Zhang D, et al. LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling. Cell Death Dis, 2018, 9(7):742.

[4] Fang Z, Zhang S, Wang Y, et al. Long non-coding RNA MALAT-1 modulates metastatic potential of tongue squamous cell carcinomas partially through the regulation of small proline rich proteins. BMC Cancer, 2016, 16:706.

[5] Zhang H, Zhao L, Wang Y X, et al. Long non-coding RNA HOTTIP is correlated with progression and prognosis in tongue squamous cell carcinoma. Tumour Biol, 2015, 36(11):8805-8809.

[6] Jia B, Xie T, Qiu X, et al. Long noncoding RNA FALEC inhibits proliferation and metastasis of tongue squamous cell carcinoma by epigenetically silencing ECM1 through EZH2. Aging (Albany NY), 2019, 11(14):4990-5007.

[7] Jun, Wang, Xuan, et al. Regulatory roles of long noncoding RNAs implicated in cancer hallmarks. International Journal of Cancer, 2019.

[8] Liu X, Zhang B, Jia Y, et al. SNHG17 enhances the malignant characteristics of tongue squamous cell carcinoma by acting as a competing endogenous RNA on microRNA-876 and thereby increasing specificity protein 1 expression. Cell Cycle, 2020, 19(6):711-725.

[9] Shao T, Huang J, Zheng Z, et al. SCCA, TSGF, and the Long Non-Coding RNA AC007271.3 are Effective Biomarkers for Diagnosing Oral Squamous Cell Carcinoma. Cellular Physiology & Biochemistry, 2018, 47:26-38.

[10] GZ H, QQ W, ZN Z, et al. Identification of Candidate Biomarkers and Analysis of Prognostic Values in Oral Squamous Cell Carcinoma. Frontiers in oncology, 2019, 9:1054.

[11] Lun A T, Chen Y, Smyth G K. It's DE-licious: A Recipe for Differential Expression Analyses of RNA-seq Experiments Using Quasi-Likelihood Methods in edgeR. Methods Mol Biol, 2016, 1418:391-416.

[12] Yu G, Wang L G, Han Y, et al. clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. Omics A Journal of Integrative Biology, 2012, 16(5):284-287.

[13] Bader G D, Hogue C W. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics, 2003, 4:2.

[14] Amelio I, Cutruzzola F, Antonov A, et al. Serine and glycine metabolism in cancer. Trends Biochem Sci, 2014, 39(4):191-198.

[15] Zeidan B, Manousopoulou A, Garay-Baquero D J, et al. Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study. Breast Cancer Res, 2018, 20(1):19.
[16] Fridley B L, Ghosh T M, Wang A, et al. Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence. Front Genet, 2016,7:37.

[17] Nagy R, Boutin T S, Marten J, et al. Exploration of haplotype research consortium imputation for genome-wide association studies in 20,032 Generation Scotland participants. Genome Med, 2017,9(1):23.

[18] Zeng J H, Liang L, He R Q, et al. Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma. Oncotarget, 2017,8(10):16811-16828.

[19] Shi X, Tan H, Le X, et al. An expression signature model to predict lung adenocarcinoma-specific survival. Cancer Manag Res, 2018,10:3717-3732.

[20] Guan C, Ouyang D, Qiao Y, et al. CA9 transcriptional expression determines prognosis and tumour grade in tongue squamous cell carcinoma patients. J Cell Mol Med, 2020,24(10):5832-5841.

[21] Chien M H, Yang J S, Chu Y H, et al. Impacts of CA9 gene polymorphisms and environmental factors on oral-cancer susceptibility and clinicopathologic characteristics in Taiwan. PLoS One, 2012,7(12): e51051.

[22] Zapata L, Pich O, Serrano L, et al. Negative selection in tumor genome evolution acts on essential cellular functions and the immunopeptidome. Genome Biol, 2018,19(1):67.

[23] Wahid B, Bashir H, Bilal M, et al. Developing a deeper insight into reproductive biomarkers. Clin Exp Reprod Med, 2017,44(4):159-170.
Table 1 DElncRNA univariate Cox regression results

| IncRNA            | HR    | z      | p-value |
|-------------------|-------|--------|---------|
| RP11-865I6.2      | 1.42  | 3.63   | 0.00028 |
| RP11-11N5.3       | 1.52  | 3.36   | 0.000787|
| AC007879.5        | 1.44  | 3.09   | 0.001999|
| RP11-109M17.2     | 1.19  | 3.05   | 0.002295|
| LINC00643         | 1.73  | 2.93   | 0.003389|
| MGC32805          | 1.37  | 2.80   | 0.005061|
| RP11-108K3.1      | 1.42  | 2.58   | 0.009793|
| RP1-35C21.2       | 1.37  | 2.57   | 0.010232|
| RP11-275N1.1      | 1.36  | 2.55   | 0.010806|
| RP3-449H6.1       | 0.47  | -2.53  | 0.011488|
| SLC8A1-AS1        | 0.71  | -2.50  | 0.012307|
| RP11-497D6.3      | 0.77  | -2.48  | 0.013248|
| LINC01615         | 1.25  | 2.46   | 0.0139  |
| FOXD2-AS1         | 1.52  | 2.46   | 0.014014|
| RP11-338H14.1     | 0.77  | -2.44  | 0.014578|
| RP11-502M1.2      | 0.74  | -2.44  | 0.014739|
| PLS3-AS1          | 1.33  | 2.43   | 0.014858|
| RP11-554D15.3     | 1.29  | 2.42   | 0.015366|
| AC005532.5        | 1.32  | 2.42   | 0.015501|
| SMC2-AS1          | 0.74  | -2.41  | 0.016186|
| AC005281.1        | 1.29  | 2.39   | 0.016625|
| LINC01191         | 0.76  | -2.39  | 0.016805|
| CTC-480C2.1       | 1.16  | 2.35   | 0.018769|
| RP11-190J1.3      | 1.17  | 2.33   | 0.019828|
| RP11-66N24.6      | 1.42  | 2.32   | 0.020159|
| PART1             | 0.87  | -2.30  | 0.021245|
| RP11-11N5.1       | 1.29  | 2.23   | 0.025701|
| Gene         | Value1   | Value2   | Value3   |
|-------------|----------|----------|----------|
| RP11-284F21.10 | 1.155663 | 2.226429 | 0.025985 |
| RP11-486A14.2  | 1.347946 | 2.220021 | 0.026417 |
| FAM87A        | 1.266124 | 2.214125 | 0.02682  |
| CTD-2527I21.14| 0.75005  | -2.21224 | 0.02695  |
| RP11-63E9.1   | 1.197589 | 2.183795 | 0.028977 |
| RP11-8L2.1    | 1.15177  | 2.181352 | 0.029157 |
| RP11-100E13.1 | 0.781413 | -2.17458 | 0.029661 |
| AC122136.2    | 1.304731 | 2.172188 | 0.029841 |
| RP11-631N16.4 | 0.78296  | -2.15329 | 0.031296 |
| RP11-284F21.9 | 1.137648 | 2.095205 | 0.036153 |
| RP13-60M5.2   | 0.81282  | -2.09177 | 0.036459 |
| LINC00052     | 1.123159 | 2.09137  | 0.036495 |
| RP11-10L7.1   | 0.759625 | -2.08643 | 0.036939 |
| FLJ43879      | 0.783353 | -2.08438 | 0.037125 |
| LINC01356     | 1.203655 | 2.063676 | 0.039048 |
| RP11-608O21.1 | 0.788421 | -2.0466  | 0.040698 |
| RP11-284F21.7 | 1.152724 | 2.028537 | 0.042506 |
| RP11-488P3.1  | 1.149669 | 2.025953 | 0.04277  |
| RP11-430C1.1  | 1.213022 | 2.015911 | 0.043809 |
| RP11-398G24.2 | 0.771309 | -2.01524 | 0.043879 |
| LINC01497     | 1.209287 | 2.006391 | 0.044815 |
| LINC01555     | 1.269332 | 1.994386 | 0.04611  |
| CTD-2184D3.5  | 1.265504 | 1.989985 | 0.046593 |
| CTD-2337I7.1  | 1.216582 | 1.967779 | 0.049093 |
| lncRNA        | β-value | HR     | z      | p-value         |
|--------------|---------|--------|--------|-----------------|
| MGC32805     | 0.77297 | 2.16619| 4.893  | 9.91E-07        |
| RP11-865I6.2 | 0.58052 | 1.78697| 4.81   | 1.51E-06        |
| RP11-11N5.3  | 0.47345 | 1.60552| 3.665  | 0.000247        |
| SLC8A1-AS1   | -0.50666| 0.6025 | -3.417 | 0.000634        |
| RP11-108K3.1 | 0.58357 | 1.79242| 3.237  | 0.001209        |
| FOXD2-AS1    | 0.61337 | 1.84665| 3.033  | 0.002423        |
| RP3-449H6.1  | -1.03457| 0.35538| -2.499 | 0.012451        |
| RP11-109M17.2| 0.12841 | 1.13702| 2.131  | 0.033116        |
| RP1-35C21.2  | 0.32227 | 1.38026| 2.124  | 0.033678        |
| PLS3-AS1     | 0.30076 | 1.35088| 2.115  | 0.034406        |
| RP11-502M1.2 | -0.2267 | 0.79716| -1.646 | 0.099728        |
| RP11-497D6.3 | -0.20679| 0.81319| -1.624 | 0.104482        |

Likelihood ratio test = 100.6 on 12 df, p = 4.331E-16
n = 146, number of events = 51
| mRNA     | HR    | z     | p-value |
|----------|-------|-------|---------|
| GNG8     | 0.668118 | -3.50266 | 0.000461 |
| CA9      | 1.272047 | 3.323934 | 0.000888 |
| OVOS2    | 0.788196 | -3.32344 | 0.000889 |
| C6       | 1.223323 | 3.273786 | 0.001061 |
| FAM65C   | 0.703648 | -3.07276 | 0.002121 |
| PCK1     | 1.22433  | 3.068226 | 0.002153 |
| GTSF1L   | 0.681065 | -3.01555 | 0.002565 |
| ODF4     | 0.632626 | -2.85445 | 0.004311 |
| C7       | 1.182026 | 2.733506 | 0.006266 |
| ADH1B    | 1.140672 | 2.710891 | 0.00671  |
| F2RL2    | 0.771353 | -2.67225 | 0.007535 |
| ADIPOQ   | 1.120641 | 2.65977  | 0.007819 |
| LRRTM3   | 1.405741 | 2.61057  | 0.009039 |
| SHOX2    | 0.742186 | -2.60479 | 0.009193 |
| ASCL4    | 0.726264 | -2.57974 | 0.009888 |
| RSPH4A   | 0.694298 | -2.57261 | 0.010093 |
| AC008810.1 | 0.617492 | -2.56539 | 0.010306 |
| HOXD9    | 0.727773 | -2.55644 | 0.010575 |
| SPINK7   | 0.908908 | -2.52329 | 0.011626 |
| KLK1     | 1.244047 | 2.516662 | 0.011847 |
| RNF212B  | 0.75701  | -2.48593 | 0.012921 |
| RIBC1    | 0.666136 | -2.47609 | 0.013283 |
| ZG16     | 1.261833 | 2.465508 | 0.013682 |
| C7orf33  | 1.307349 | 2.463732 | 0.01375  |
| SFTPc    | 1.177867 | 2.44232  | 0.014593 |
| CASP14   | 1.112717 | 2.428729 | 0.015152 |
| AL590235.1 | 0.721791 | -2.42216 | 0.015428 |
| Gene       | Value_1     | Value_2     | p-value   |
|------------|-------------|-------------|-----------|
| KLF7       | 1.563083    | 2.419143    | 0.015557  |
| TTC16      | 0.778389    | -2.40787    | 0.016046  |
| CFAP73     | 0.726075    | -2.38832    | 0.016925  |
| MOV10L1    | 0.759161    | -2.37089    | 0.017745  |
| SOX1       | 1.133833    | 2.358584    | 0.018345  |
| FGA        | 1.136625    | 2.347279    | 0.018911  |
| KCNJ16     | 1.18101     | 2.346808    | 0.018935  |
| CXCL13     | 0.842367    | -2.33704    | 0.019437  |
| DNAAF1     | 0.750386    | -2.32597    | 0.02002   |
| KRT33A     | 0.808128    | -2.29248    | 0.021878  |
| KRT39      | 1.284344    | 2.28228     | 0.022473  |
| NXPH1      | 1.311622    | 2.270645    | 0.023168  |
| SOHLH1     | 1.087993    | 2.268472    | 0.0233    |
| CGNL1      | 0.815958    | -2.26673    | 0.023407  |
| KRT33B     | 0.825259    | -2.26171    | 0.023715  |
| RTP3       | 0.882223    | -2.23521    | 0.025403  |
| CLVS2      | 1.261847    | 2.228258    | 0.025863  |
| DNER       | 1.156868    | 2.215978    | 0.026693  |
| INSM1      | 0.81694     | -2.21324    | 0.026881  |
| TCEAL6     | 1.465081    | 2.212831    | 0.026909  |
| AMTN       | 0.910094    | -2.19567    | 0.028116  |
| AQP7       | 1.177243    | 2.175438    | 0.029597  |
| ALB        | 1.119201    | 2.172115    | 0.029847  |
| ETNPPL     | 1.210195    | 2.169777    | 0.030024  |
| GJB7       | 1.117709    | 2.166463    | 0.030276  |
| TMEM232    | 1.347199    | 2.16267     | 0.030567  |
| CST5       | 1.230666    | 2.144369    | 0.032003  |
| FGG        | 1.13366     | 2.140215    | 0.032337  |
| HIST1H3G   | 1.197317    | 2.136028    | 0.032677  |
| Gene       | Value1  | Value2  | Value3   |
|------------|---------|---------|----------|
| C14orf180  | 1.316759| 2.11975 | 0.034027 |
| SLC6A4     | 0.825596| -2.11584| 0.034358 |
| PTCH2      | 0.747119| -2.1061 | 0.035196 |
| PPP1R3C    | 1.179677| 2.104002| 0.035378 |
| AC009060.2 | 0.814285| -2.09827| 0.035881 |
| PLIN4      | 1.1366  | 2.091326| 0.036499 |
| CAPS       | 0.745138| -2.08551| 0.037023 |
| SSX1       | 0.723928| -2.08103| 0.037431 |
| HIST1H2AG  | 1.27392 | 2.072023| 0.038263 |
| HTN3       | 1.125145| 2.071847| 0.03828 |
| CGB8       | 0.868005| -2.07144| 0.038318 |
| TSNAXIP1   | 0.704588| -2.06564| 0.038862 |
| PLIN1      | 1.141516| 2.061308| 0.039274 |
| JAML       | 0.800447| -2.05423| 0.039954 |
| GOLGA6L2   | 0.843113| -2.05132| 0.040235 |
| PAGE1      | 0.613576| -2.04904| 0.040458 |
| CASC1      | 0.79658 | -2.04356| 0.040997 |
| PLPPR5     | 0.838986| -2.04324| 0.041029 |
| IL36A      | 0.913631| -2.03106| 0.042249 |
| CLEC3B     | 0.803616| -2.03096| 0.042259 |
| SERPINA9   | 0.874336| -2.02217| 0.043159 |
| RNF224     | 0.832738| -2.02016| 0.043367 |
| CFD        | 1.208165| 2.00777 | 0.044668 |
| SMR3B      | 1.119902| 2.001821| 0.045304 |
| WDR38      | 0.799472| -1.98747| 0.04687 |
| SGIP1      | 0.789217| -1.98572| 0.047065 |
| RIMS4      | 1.157784| 1.973463| 0.048443 |
| APELA      | 0.868882| -1.9734 | 0.04845 |
| LAMB4      | 0.863059| -1.97128| 0.048692 |
|     |          |        |          |
|-----|----------|--------|----------|
| KLK12 | 0.917869 | -1.9689 | 0.048965 |
| ANGPTL5 | 1.234164 | 1.968716 | 0.048986 |
| LAIR2 | 0.837717 | -1.96821 | 0.049044 |
| CFAP43 | 0.789604 | -1.96655 | 0.049235 |
| MMP19 | 0.768498 | -1.96345 | 0.049594 |
Table 4 DEmRNA multivariate Cox regression results

| mRNA   | β-value | HR    | z     | p-value   |
|--------|---------|-------|-------|-----------|
| CA9    | 0.35074 | 1.42012 | 4.573 | 4.81E-06  |
| OVOS2  | -0.30854 | 0.73452 | -3.52 | 0.000432  |
| LRRTM3 | 0.51937 | 1.68097 | 3.322 | 0.000893  |
| C7     | 0.24123 | 1.27282 | 3.001 | 0.002687  |
| GTSF1L | -0.4969 | 0.60841 | -2.874 | 0.004059 |
| PCK1   | 0.23855 | 1.26941 | 2.745 | 0.006049  |
| F2RL2  | -0.27071 | 0.76284 | -2.318 | 0.020465 |
| ODF4   | -0.33474 | 0.71552 | -2.153 | 0.03131   |

Likelihood ratio test=80.93 on 8 df, p=3.179E-14

n= 146, number of events= 51
FIGURE 1 Heatmap of 1,001 DElncRNAs (A) and 2,006 DEmRNAs (B) (|log2FC| >2.0 and adjusted $p < 0.05$). Red indicates upregulation, green indicates downregulation, and black indicates normal expression. Each column represents a sample, and each row represents a differentially expressed gene. Similar to that in the heatmap, red indicates upregulation, green indicates downregulation, and black indicates normal expression in the volcano plot. Each point represents a gene.

FIGURE 2 GO and KEGG pathway analysis of the DEmRNAs. (C) The numbers of genes enriched in each GO category. The y axis represents the GO categories including the biological process, cellular component and molecular function categories, and the x axis represents the enrichment score. Furthermore, the color represents the $q$-value. (D) The top 10 pathways enriched in the DEmRNAs. The y axis represents the pathways, the x axis represents enriched gene numbers, and the color indicates the $p$-value.

FIGURE 3 The significant prognostic value of DElncRNAs, including AC007879.5, FOXD2-AS1, LINC01615, MGC32805, PLS3-AS1, RP1-35C21.2, RP11-108K3.1, RP11-109M17.2, RP11-275N1.1, RP11-497D6.3, and RP11-502M1.2.

FIGURE 4 The significant prognostic value of DEmRNAs, including ADH1B, ASCL4, C6, CA9, FAM65C, GNG8, GTSF1L, ODF4, OVOS2, PCK1, and SHOX2.

FIGURE 5 The survival rate of the low-risk patients was significantly higher than that of the high-risk patients (E). The heatmap shows the relationships between the expression of 12 candidate DElncRNAs and the risk score of each patient (F). The 5-year survival correlation of the 12 DElncRNAs was assessed by ROC analysis, and AUCs were computed to assess the discriminatory capacity of the lncRNA signature (G). Similar to that for DElncRNAs, risk score analysis (H) of eight candidate DEmRNAs was performed for each patient and a heatmap was constructed (I). Subsequently, the ROC curve was plotted, and the AUC was 0.84 (J).

FIGURE 6 The expression of FOXD2-AS1, MGC32805, PLS3-AS1, RP1-35C21.2, RP11-108K3.1 and RP11-109M17.2 was analyzed in TSCC and normal tissues and in the paired groups.
FIGURE 7 The expression of CA9, GTSF1L, ODF4, OVOS2, and PCK1 was analyzed in TSCC and normal tissues and in the paired groups.

FIGURE 8 Forest map of MGC32805, RP1-35C21.2, RP11-108K3.1, RP11-109M17.2, CA9, and GTSF1L based on the risk score model.

FIGURE 9 The GSEA results of MGC32805, RP1-35C21.2, RP11-108K3.1, RP11-109M17.2, CA9, and GTSF1L.

FIGURE 10 Three subnetworks of weighted gene coexpression network analysis were constructed using the MCODE tool of Cytoscape.

FIGURE 11 A total of 103 genes were selected to construct the three PPI subnetworks with degree>=20 by using the MCODE tool.

FIGURE 12 qRT-PCR validation of six biomarkers from sequencing (**p<0.001, *p<0.05).